Tenax Therapeutics Stock Analysis

TENX Stock  USD 5.94  0.02  0.34%   
Tenax Therapeutics is undervalued with Real Value of 9.16 and Target Price of 18.85. The main objective of Tenax Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Tenax Therapeutics is worth, separate from its market price. There are two main types of Tenax Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tenax Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tenax Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Tenax Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Tenax Stock Analysis Notes

About 67.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.23. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tenax Therapeutics last dividend was issued on the 26th of February 2018. The entity had 1:80 split on the 3rd of January 2024. Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. Tenax Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Tenax Therapeutics contact Christopher Giordano at 919 855 2100 or learn more at https://www.tenaxthera.com.

Tenax Therapeutics Investment Alerts

Tenax Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (17.6 M) with profit before overhead, payroll, taxes, and interest of 0.
Tenax Therapeutics currently holds about 7.23 M in cash with (14.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Tenax Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 67.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Tenax Therapeutics Upcoming and Recent Events

Earnings reports are used by Tenax Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
12th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Tenax Largest EPS Surprises

Earnings surprises can significantly impact Tenax Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-13
2023-09-30-0.09-0.080.0111 
2022-05-16
2022-03-31-0.09-0.11-0.0222 
2023-08-14
2023-06-30-0.1-0.050.0550 
View All Earnings Estimates

Tenax Therapeutics Environmental, Social, and Governance (ESG) Scores

Tenax Therapeutics' ESG score is a quantitative measure that evaluates Tenax Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Tenax Therapeutics' operations that may have significant financial implications and affect Tenax Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Tenax Stock Institutional Investors

Shares
Geode Capital Management, Llc2025-03-31
33.3 K
Millennium Management Llc2025-03-31
26.6 K
Citadel Advisors Llc2025-03-31
23.1 K
Vanguard Group Inc2025-03-31
22.3 K
Dimensional Fund Advisors, Inc.2025-03-31
19.2 K
Ubs Group Ag2025-03-31
2.9 K
Blackrock Inc2025-03-31
300
Bank Of America Corp2025-03-31
229
Tower Research Capital Llc2025-03-31
192
Rtw Investments, Llc2025-03-31
378.3 K
Bvf Inc2025-03-31
339.5 K
Note, although Tenax Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tenax Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.73 M.

Tenax Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.18)(0.19)
Return On Capital Employed(0.21)(0.20)
Return On Assets(0.18)(0.19)
Return On Equity(0.19)(0.18)

Management Efficiency

Tenax Therapeutics has return on total asset (ROA) of (0.266) % which means that it has lost $0.266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3978) %, meaning that it created substantial loss on money invested by shareholders. Tenax Therapeutics' management efficiency ratios could be used to measure how well Tenax Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.19 in 2025. Return On Capital Employed is likely to rise to -0.2 in 2025. At this time, Tenax Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.9 M in 2025, whereas Non Current Assets Total are likely to drop 0.00 in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 6.02  5.72 
Tangible Book Value Per Share 6.02  5.72 
Enterprise Value Over EBITDA 0.02  0.02 
Price Book Value Ratio 1.03  0.98 
Enterprise Value Multiple 0.02  0.02 
Price Fair Value 1.03  0.98 
Enterprise Value-367 K-348.7 K
Leadership effectiveness at Tenax Therapeutics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta
1.622
Return On Assets
(0.27)
Return On Equity
(0.40)

Technical Drivers

As of the 21st of July, Tenax Therapeutics has the Risk Adjusted Performance of 0.0656, semi deviation of 2.4, and Coefficient Of Variation of 1577.98. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tenax Therapeutics, as well as the relationship between them.

Tenax Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Tenax Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Tenax Therapeutics short-term fluctuations and highlight longer-term trends or cycles.

Tenax Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenax Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenax Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenax Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Christopher Giordano over two months ago
Acquisition by Christopher Giordano of 1400000 shares of Tenax Therapeutics at 5.89 subject to Rule 16b-3
 
Dellora Investments Lp over six months ago
Insider Trading
 
Armistice Capital, Llc over six months ago
Acquisition by Armistice Capital, Llc of tradable shares of Tenax Therapeutics subject to Rule 16b-3
 
Christopher Giordano over six months ago
Acquisition by Christopher Giordano of 1250000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3
 
Almenoff June Sherie over six months ago
Acquisition by Almenoff June Sherie of 100000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3
 
Mcgauley Thomas over six months ago
Insider Trading
 
Rich Stuart over six months ago
Acquisition by Rich Stuart of 100000 shares of Tenax Therapeutics at 0.62 subject to Rule 16b-3
 
Davidson Michael H. over six months ago
Acquisition by Davidson Michael H. of 47500 shares of Tenax Therapeutics at 0.01 subject to Rule 16b-3
 
Davidson Michael H. over six months ago
Acquisition by Davidson Michael H. of 25000 shares of Tenax Therapeutics at 4.5 subject to Rule 16b-3
 
Davidson Michael H. over six months ago
Acquisition by Davidson Michael H. of 2500 shares of Tenax Therapeutics at 3.0 subject to Rule 16b-3
 
Armistice Capital, Llc over a year ago
Acquisition by Armistice Capital, Llc of 4773269 shares of Tenax Therapeutics at 1.0E-4 subject to Rule 16b-3
 
Rich Stuart over a year ago
Acquisition by Rich Stuart of 3581000 shares of Tenax Therapeutics subject to Rule 16b-3

Tenax Therapeutics Outstanding Bonds

Tenax Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenax Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenax bonds can be classified according to their maturity, which is the date when Tenax Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Tenax Therapeutics Predictive Daily Indicators

Tenax Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tenax Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Tenax Therapeutics Corporate Filings

F4
3rd of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
30th of June 2025
Other Reports
ViewVerify
8K
17th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
20th of May 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
15th of May 2025
Other Reports
ViewVerify
14th of May 2025
Other Reports
ViewVerify
25th of April 2025
Other Reports
ViewVerify
23rd of April 2025
Other Reports
ViewVerify

Tenax Therapeutics Forecast Models

Tenax Therapeutics' time-series forecasting models are one of many Tenax Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tenax Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Tenax Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Tenax Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tenax shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tenax Therapeutics. By using and applying Tenax Stock analysis, traders can create a robust methodology for identifying Tenax entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(352.38)(334.76)
Operating Profit Margin(364.89)(346.65)
Net Loss(328.57)(312.15)
Gross Profit Margin 0.72  0.76 

Current Tenax Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tenax analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tenax analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
18.85Strong Buy4Odds
Tenax Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Tenax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tenax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tenax Therapeutics, talking to its executives and customers, or listening to Tenax conference calls.
Tenax Analyst Advice Details

Tenax Stock Analysis Indicators

Tenax Therapeutics stock analysis indicators help investors evaluate how Tenax Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tenax Therapeutics shares will generate the highest return on investment. By understating and applying Tenax Therapeutics stock analysis, traders can identify Tenax Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow9.8 M
Common Stock Shares Outstanding15.3 M
Total Stockholder Equity92 M
Cash And Short Term Investments94.9 M
Cash94.9 M
Accounts Payable3.2 M
Net Debt-94.9 M
50 Day M A5.8577
Total Current Liabilities4.7 M
Other Operating Expenses19.5 M
Forward Price Earnings0.299
Stock Based Compensation1.1 M

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.